Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

STM-01: Phase I EffTox Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy of Solid Tumors

NCT01639911 is registered in ClinicalTrials.gov with University of Illinois at Chicago as lead sponsor.

NCT NCT01639911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01639911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
STM-01: Phase I EffTox Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy of Solid Tumors
Lead sponsor
University of Illinois at Chicago
Phase
Phase 1
Overall status
Completed
Start date
August 14, 2013
Completion date
July 28, 2016
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cns malignancy, genitourinary neoplasms malignancy and gender unspecified, head and neck neoplasms, malignant neoplasm of breast, malignant neoplasm of gastrointestinal tract, malignant neoplasm of thorax, melanoma